The present disclosure relates to fusion proteins for inducing immune response and treating cancer, and particularly to fusion proteins for use as an immunogenic enhancer for inducing humoral immune response and cell-mediated immune response.

The present invention relates to the fusion proteins against a glycocalyx, found to be associated with several human post-translational modified proteins linked to cancer cell lines. The fusion proteins of the present invention are able to bind only to sialylated glycosphingolipids and sialylated glycoproteins and well as their independent constituents the monosaccharide sugars such as neu5ac, galnac and gal that constitute the glycocalyx. The products claimed can be used for diagnosis and treatment of various cancers. Apoptosis via Caspase 3 occurs in cancer cells when the fusion protein bound to targets is sequestered in lysosomes. The fusion protein is not seen in any other organelle of the cell except for lysosomes.

Disclosed herein is a glycoengineered tumor cell or a glycoengineered tumor cell fragment for use in treatment and/or prevention of cancer, in particular cancerous neoplasms, in a subject. The glycoengineered tumor cell or tumor cell fragment includes a tumor cell surface including one or more carbohydrate antigen moieties. Furthermore, a pharmaceutical composition including such a cell or cell fragment, a method for producing such a glycoengineered tumor cell or tumor cell fragment and a method of treatment of a subject including the administration of such a glycoengineered tumor cell or glycoengineered tumor cell fragment to a subject is disclosed.

The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.